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Purpose:We compared the gene expression profile of peripheral blood CD34+ cells and granulocytes in subjects
with chronic myeloid leukemia (CML), with the accent on signaling pathways affected by BCR–ABL oncogene.
Methods: Themicroarray analyses have beenperformed in circulating CD34+ cells and granulocytes fromperiph-
eral blood of 7 subjects with CML and 7 healthy donors. All studied BCR–ABL positive CML patientswere in chron-
ic phase, with a mean value of 2012 ± SD of CD34+ cells/μl in peripheral blood.
Results: The gene expression profile was more prominent in CML CD34+ cells (3553 genes) compared to
granulocytes (2701 genes). The 41 and 39 genes were significantly upregulated in CML CD34+ cells (HINT1,
TXN, SERBP1) and granulocytes, respectively. BCR–ABL oncogene activated PI3K/AKT andMAPK signaling through
significant upregulation of PTPN11, CDK4/6, andMYC and reduction of E2F1, KRAS, andNFKBIA gene expression in
CD34+ cells. Among genes linked to the inhibition of cellular proliferation by BCR–ABL inhibitor Imatinib, the FOS
and STAT1 demonstrated significantly decreased expression in CML.
Conclusion: The presence of BCR–ABL fusion gene doubled the expression quantity of genes involved in the
regulation of cell cycle, proliferation and apoptosis of CD34+ cells. These results determined the modified
genes in PI3K/AKT and MAPK signaling of CML subjects.© 2015 Elsevier Inc. All rights reserved.1. Introduction
Chronicmyeloid leukemia (CML) is a clonalmyeloproliferative disor-
der that originates from an abnormal pluripotent bonemarrow hemato-
poietic stem cell, characterized by various biological and clinical features
[1]. The main molecular marker of CML is the BCR–ABL fusion gene gen-
eration as a result of a t(9;22)(q34;q11) translocation [2]. It has been
shown that distribution of malignant cells in CML is not induced by the
neoplastic stem cell, but by the lineage-committed progenitor cells [3].
During the chronic phase CML, pool of circulated CD34+ cells demon-
strate an increase in the proportion of megakaryocyte–erythroid pro-
genitors, whereas the proportion of hematopoietic stem cells and
granulocyte–macrophage progenitors usually decrease [4]. The gene ex-
pression profiles of quiescent bone marrow leukemic and peripheral
blood CD34+ cells of untreated CML subjects demonstrate no significant
difference compared to normal CD34+ cells [4,5]. The sedentary CMLntal hematology, Institute for
1129 Belgrade, Serbia.CD34+ cells are more similar to their dividing counterparts than quies-
cent normal cells are to theirs [6].
In patients with CML, mitogenic signaling pathways such as rat sar-
coma viral oncogenes homolog (RAS)/mitogen-activated protein kinase
(MAPK) pathway, the Janus kinase (JAK)/signal transducer and activa-
tor of transcription (STAT) pathway, phosphoinositide-3 kinase
(PI3K)/AKT pathway and the MYC pathway are usually constitutively
activated, in addition to the deregulation of proliferation, apoptosis
and release of progenitors from the bone marrow [7]. The following
cellular processes are dysregulated by the BCR–ABL oncoprotein: RAS/
MAPK signaling that activates proliferation, and PI3K/AKT signaling
that activates apoptosis. It has been shown that most components of
the MAPK and PI3K/AKT pathways and some genes of the alternative
JNK and p38 MAPK pathways are upregulated in primary CML CD34+
cells [4]. A wide range of genes are identified as being dependent on
BCR–ABL1-mediated signaling, including genes involved in signal trans-
duction of JAK/STAT, MAPK, and transforming growth factor-beta (TGF-
β). BCR–ABL1 activates several genes involved in negative feedback reg-
ulation that indirectly suppress the tumor promoting effects exerted by
BCR–ABL1 [8].
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on selected CD34+ cells or mononuclear cells [9–12]. In our study we
combined gene expression analyses of selected CD34+ cells and
granulocytes to determine persistent and transient gene expression in
MAPK, PI3K/AKT and TGF-β pathways, influenced by BCR–ABL, during
cell maturation. Gene expression patterns reflect BCR–ABL-induced
functional modifications such as cell-cycle, apoptosis and proliferation.
This observation highlights the difference in gene expression between
CD34+ cells of CML and control subjects, with the accent on genes
that direct the pathogenic course of malignancy.
2. Material and methods
2.1. Isolation of CD34+ cells and granulocytes from the peripheral blood of
CML subjects
Informed consent was obtained from 7 de novo subjects with CML
included in the study. All subjects had signed the consent form ap-
proved by the local ethical committee. All studied de novo CML subjects
were subject to 10ml of peripheral blood draw on one occasion, collect-
ed in 10% sodium citrate. The maximum time interval between
venepuncture and arrival in the laboratory was 2 h. Each 20 ml of dilut-
ed blood (1:1with Ca2+/Mg2+-free PBS)was then layered gently on the
top of 10 ml lymphocyte separation medium (LSM, PAA Laboratories
GmbH, Pasching, Austria). After centrifugation (400 g, 30 min, 20 °C),
the interface containing mononuclear cells was collected and washed
with PBS. The CD34+ cells were isolated from the collectedmononucle-
ar cells using a positive immunomagnetic separation (Super Macs II,
Miltenyi Biotec, Bergisch Gladbach, Germany). Control CD34+ cells
were also isolated by positive immunomagnetic separation from 7
leukapheresis products of healthy donors (4 females, 3 males). The pel-
let formed during centrifugation with LSM was comprised mostly of
erythrocytes and granulocytes that migrated through the gradient.
The erythrocytes were removed by using lysing solution (0.15 M
NH4Cl, 0.1 mM Na2EDTA, 12 mM NaHCO3). High quality of purified
granulocytes was confirmed by cytospin preparations and Wright–
Giemsa staining. The viable CD34+ cell and granulocyte counts were
performed by trypan-blue exclusion technique (BioWhittaker). The
purity of recovered cells was determined by flow cytometry using PE-
anti-CD34 mAb (BD Biosciences, San Jose, CA, USA) and was over 80%
in samples used for microarray analysis. Karyotype analyses confirmed
the Philadelphia chromosome aberrations t(9:22)(q34:q11) in all exam-
ined CML subjects.
2.2. Isolation of total RNA
We use the RNeasy protocol for isolation of total RNA from CD34+
cells and granulocytes according to the manufacturer's instructions
(Qiagen GmbH, Hilden, Germany). Concentration and integrity of total
RNA were assessed using the NanoDrop spectrophotometer (Thermo
Fisher Scientific Inc., Wilmington, Delaware, USA) and Agilent 2100
Bioanalyzer Software (Agilent Technologies, Waldbronn, Germany)
comparing the ratio of 28S and 18S RNA peaks to ensure that there is
minimal degradation of the RNA sample.
2.3. Microarray analysis
The human oligo probe set is purchased from Operon Human ge-
nome Array-Ready Oligo Set Version 4.0 (Eurofins MWG Operon,
Huntsville, AL, USA) which contains 35,035 oligonucleotide probes,
representing approximately 25,100 unique genes. The human version
4.0 is constructed based on the Ensemble human database build
(NCBI-35c), with a full coverage on NCBI human Refseq dataset. We
have followed the MIAME (minimum information about a microarray
experiment) guidelines for the data presentation. Oligonucleotides
were diluted in 150 mM sodium phosphate, pH 8.5, at 20 μMconcentration for printing. Also, our prior experience with these prima-
ry cell cultures includes quantitative PCRwith housekeeping genes (S16
and HPRT) to establish similar efficiency of cDNA synthesis and PCR
(data not shown). In microarray studies, for determination of broad
gene expression in CD34+ cells, we analyzed 7 CML subjects in chronic
phase (1 female and 6 males, average age 60) and 7 healthy subjects (4
females and3males, average age 48). For determination of gene expres-
sion in granulocytes we used 2 CML subjects (1 female and 1 male, av-
erage age 58) in chronic phase and 4 healthy subjects (2 females and
2 males, average age 51), that matched subjects used for isolation of
CD34+ cells.
2.4. Amplification of mRNA
We isolated a low quantity of CD34+ cells (~2 × 106 cells) that cor-
respond to low mRNA levels insufficient for microarray analysis, so we
performed the amplification of total RNA using the Amino Allyl
MessageAmp™ II aRNAAmplification kit (Life Technologies Corp., Carls-
bad, CA, US). This amplification protocol was performed both in CD34+
cells and granulocytes, for parallel studies, according to the
manufacturer's instructions. We used 0.5 μg of total RNA from CML sub-
jects for amplification. Briefly, 11 μl of total RNAwas mixed with 1 μl of
T7 dT primer and incubated at 70 °C for 5 min and quickly chilled for
3 min. Then, 8 μl Reverse Transcription Master Mix (10× First Strand
Buffer, dNTP Mix, Rnase inhibitor, ArrayScript) was added and incubat-
ed for 2 h at 42 °C and quickly chilled. We added 80 μl Second Strand
Master Mix (10× Second Strand Buffer, dNTP Mix, DNA polymerase,
Rnase H) and incubated for 2 h at 16 °C. cDNA was purified by 250 μl
cDNA Binding buffer and the mixture applied to the cDNA filter car-
tridge. After discharging the flow-through, 500 μl of washing buffer
was added to the column, and centrifuged for 1 min at 10,000 rpm.
cDNA was diluted with 18 μl of 55 °C preheated nuclease free water,
mixed with 26 μl of in vitro transcription (IVT) Master Mix (aaUTP,
ATP, CTP, GTP mix, UTP solution, 10× reaction buffer, T7 enzyme mix)
and after 14 h incubation at 37 °C we added 60 μl of nuclease free
water. Amino allyl-modified antisense RNA (aRNA) was purified with
aRNA Binding buffer and ethanol, applied to the cDNA filter column
and quantified by the NanoDrop spectrophotometer (Thermo Fisher
Scientific Inc.). Vacuumdried 3 μg of aRNAwas resuspended in 9 μl Cou-
pling buffer, mixed with 11 μl Cy5 dye resuspended in DMSO and incu-
bated 45 min at room temperature (RT) in the dark. After incubation,
labeled aRNA was purified and eluted with 10 μl preheated nuclease
free water by centrifugation.
2.5. Probe preparation
Total human universal RNA (HuURNA) isolated from a collection of
adult human tissues to represent a broad range of expressed genes
from both male and female donors (BD Biosciences, Palo Alto, CA)
served as a universal reference control in the competitive hybridization.
All examined CML and healthy control samples are hybridized against
HuURNA. Briefly, 5 μg of HuURNA was incubated at 70 °C for 5 min
along with 1 μl of aminoallyl-oligo dT primer and quickly chilled for
3 min. Then, 2 μl 10× first strand buffer, 1.5 μl SSII enzyme (Stratagene,
La Jolla, CA), 1.5 μl 20× aminoallyl dUTP and 2 μl of 0.1 M DTT were
added and incubated for 90 min at 42 °C. After incubation, volume of
the reaction mixture was raised to 60 μl with 40 μl of DEPC water.
cDNA was purified by the MinElute column (Qiagen) where 300 μl of
Binding buffer PB was added to the coupled cDNA, and the mixture ap-
plied to the MinElute column, and centrifuged for 1 min at 10,000 rpm.
After discharging the flow-through, 500 μl of washing buffer PE was
added to the column, and centrifuged for 1 min at 10,000 rpm. The
flow-through was discharged and the washing repeated. Then the col-
umns were placed into a fresh Eppendorf tube and 10 μl elution buffer
added to the membrane, incubated for 1 min at RT, centrifuged for
1 min at 10,000 rpm and probe collected. The probe was dried in
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buffer was mixed with 10 μl of Cy3 dye (GE Healthcare Bio-Sciences
Corp., Piscataway, NJ), diluted in DMSO, and incubated at RT in the
dark for 90 min. After incubation, the volume was raised to 60 μl by
40 μl DEPC water and then cDNA was purified by the MinElute column
and eluted with 10 μl elution buffer by centrifugation. Eluted cDNA
probe and aRNA were combined in the final volume of 20 μl for
hybridization.
2.6. Hybridization
For hybridization, the mixture of cDNA probe and aRNA was
preheated at 100 °C for 2 min and centrifuged for 1 min at
10,000 rpm. 20 μl of preheated (42 °C) Ambion hybridization buffer
(20× SSC and 10% SDS) is mixed with hybridization mixture. Total vol-
ume of the hybridization mixture was added on the array in slide and
covered with cover slip. Slides were placed in MAUI hybridization
chamber (BioMicro Systems, Inc., Salt Lake City, UT, USA) and incubated
overnight at 42 °C. Slides were then washed each in 1× SSC and 0.1×
SSC and spin-dried.
2.7. Data filtration, normalization and analysis
Microarray slides were scanned in both Cy3 (532 nm) and Cy5
(635 nm) channels using anAxon GenePix 4000B scanner (Axon Instru-
ments, Inc., Foster City, CA) with a 10-μm resolution. Scanned microar-
ray images were exported as TIFF files to GenePix Pro 3.0 software for
image analysis. The raw images were collected at 16-bit/pixel resolu-
tions with 0 to 65,535 count dynamic range. The area surrounding
each spot image was used to calculate a local background and
subtracted from each spot before the Cy5:Cy3 ratio calculation. The
average of the total Cy3 and Cy5 signal gave a ratio that was used to
normalize the signals. Each microarray experiment was globally nor-
malized to make the median value of the log2-ratio equal to zero. The
Loess normalization process corrects for dye bias, photo multiplier
tube voltage imbalance and variations between channels in the
amounts of the hybridized labeled cDNA probes. The data files
representing the differentially expressed genes were then created. For
advanced data analysis, gpr and jpeg files were imported into microar-
ray database and normalized by software tools provided by the NIH
Center for Information Technology (http://nciarray.nci.nih.gov/). SpotsFig. 1.Microarray study of gene expression in CD34+ cells and granulocytes fromperipheral blo
and control (N= 7) CD34+ cells. (B) The Venn diagram shows similarity of gene expression be
ilarity of gene expression between CML and control granulocytes. (D) The Venn diagram showwith a confidence interval of 99% (≥2 fold)with a fluorescence intensity
of at least 150 for both channels and 30 μm spot sizewere considered as
good quality spots for analysis. The complete results of our microarray
experiments are available in the gene expression omnibus database
(http://www.ncbi.nlm.nih.gov/geo; accession no. GSE55976) according
to MIAME standards.
2.8. Statistical analysis
For microarray data management and analysis, we used NCI/CIT mi-
croArray database (mAdb) system. The one way ANOVA was applied
using mAdb software for measurement of statistical significance in
gene expression in CML. For mAdb hierarchical clustering we used
uncentered correlation that applies a modified Pearson correlation
equation. It is basically the same as the standard Pearson correlation
function, except that it assumes that the means are 0.
3. Results
3.1. Comparison of gene expression between CML subjects and controls in
CD34+ cells and granulocytes
The t(9;22)(q34;q11) translocation was present in all CML subjects,
with an average of 2012 CD34+ cells/μl (SD ± 3158) and 56 × 109/l
granulocytes (SD ± 44) in peripheral blood. In controls, the average
number was 3.1 ± 1.4 CD34+ cells/μl, but through leukapheresis we
separated 5.7 × 105 CD34+ cells per control subject. Within CML and
control subjects the average correlation was high: CML— 0.89 and con-
trols— 0.88 (Supplemental Table 1). Also, the average correlation coef-
ficient was even higher among granulocytes: Controls — 0.93 and CML
— 0.94. Using the Venn diagramwe compared the total gene expression
in CD34+ cells from control and CML subjects before and after 50% fil-
tration (Fig. 1A, B). The total gene expression in CD34+ CML cells
revealed 6457 genes, while after filtration of 50% the total gene expres-
sion was reduced to 3553 genes determined by microarray analysis
(Fig. 1A, B). Before filtration, the total gene expression in granulocyte
revealed 3947 genes, while after 50% filtration this number declined
to 2701 genes (Fig. 1C, D). Therefore, the total gene expression
was almost doubled in CD34+ CML cells compared to granulocytes
after 50% filtration (Fig. 1). The 64 genes overexpressed, more than
2-fold, exclusively in CML CD34+ cells are presented in Table 1.od. (A) The Venn diagram shows similarity of total gene expression between CML (N= 7)
tween CML and control CD34+ cells after 50% filtration. (C) The Venn diagram shows sim-
s similarity of gene expression between CML and control granulocytes after 50% filtration.
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DEFA1/3 and MPO (Table 1). Genes overexpressed exclusively in
CML granulocytes more than 2 fold were lectin galactoside-binding
soluble 16 (LGALS16), hyperpolarization activated cyclic nucleotide
gated potassium channel 3 (HCN3), chemokine (C–C motif) ligandTable 1




DEFA3 Defensin, alpha 3, neutrophil-specific 6.38 0.30
DEFA1 Defensin, alpha 1 6.35 0.30
MPO Myeloperoxidase 4.63 1.39
HSH2D Hematopoietic SH2 domain containing 3.96 0.24
FBXO4 F-box protein 4 3.65 0.47
MLLT3 Myeloid/lymphoid or mixed-lineage leukemia 3.47 0.42
SRSF7 Serine/arginine-rich splicing factor 7 3.47 0.40
CHST13 Carbohydrate (chondroitin 4) sulfotransferase 13 3.18 0.43
ZNF180 Zinc finger protein 180 3.10 0.38
LIMS1 LIM and senescent cell antigen-like domains 1 2.96 0.34
KCNH2 Potassium voltage-gated channel, subfamily H 2.94 1.12
PLAC8 Placenta-specific 8 2.90 0.79
TRMT2B tRNA methyltransferase 2 homolog B 2.86 0.39
HTRA3 HtrA serine peptidase 3 2.84 0.95
GFI1 Growth factor independent 1 transcription repressor 2.83 1.10
PHF14 PHD finger protein 14 2.80 0.25
USP38 Ubiquitin specific peptidase 38 2.79 0.30
CASP6 Caspase 6, apoptosis-related cysteine peptidase 2.73 0.25
SLC39A8 Solute carrier family 39 (zinc transporter), member 8 2.72 0.57
ERLIN1 ER lipid raft associated 1 2.61 0.20
CD33 CD33 molecule 2.59 0.56
N4BP2L2 NEDD4 binding protein 2-like 2 2.57 0.41
CREB3L4 cAMP responsive element binding protein 3-like 4 2.55 0.34
RARRES3 Retinoic acid receptor responder 2.52 0.44
CASP3 Caspase 3, apoptosis-related cysteine peptidase 2.52 0.59
ASB8 Ankyrin repeat and SOCS box containing 8 2.51 0.33
CPT2 Carnitine palmitoyltransferase 2 2.49 0.43
MAGEH1 Melanoma antigen family H, 1 2.48 0.77
SBNO1 Strawberry notch homolog 1 2.48 0.37
CRBN Cereblon 2.47 0.47
TMEM69 Transmembrane protein 69 2.45 0.33
KLF6 Kruppel-like factor 6 2.43 0.35
LSM10 LSM10, U7 small nuclear RNA associated 2.43 1.57
DCUN1D1 DCN1, defective in cullin neddylation 1, domain cont 1 2.37 0.33
FAM175A Family with sequence similarity 175, member A 2.36 0.36
FBXW9 F-box and WD repeat domain containing 9 2.34 0.79
EEF1A1 Eukaryotic translation elongation factor 1 alpha 1 2.32 0.45
EED Embryonic ectoderm development 2.32 0.42
AFF3 AF4/FMR2 family, member 3 2.28 0.39
OIP5 Opa interacting protein 5 2.26 0.60
THEM4 Thioesterase superfamily member 4 2.23 0.29
UBE2V2 Ubiquitin-conjugating enzyme E2 variant 2 2.19 0.27
MRPL19 Mitochondrial ribosomal protein L19 2.18 0.12
XK X-linked Kx blood group (McLeod syndrome) 2.18 0.95
ISY1 ISY1 splicing factor homolog 2.17 0.21
MINPP1 Multiple inositol-polyphosphate phosphatase 1 2.16 0.53
USP48 Ubiquitin specific peptidase 48 2.16 0.33
PXMP2 Peroxisomal membrane protein 2, 22 kDa 2.14 0.39
BCCIP BRCA2 and CDKN1A interacting protein 2.11 0.31
ARMCX1 Armadillo repeat containing, X-linked 1 2.10 0.39
CHEK1 Checkpoint kinase 1 2.08 0.53
BDH2 3-Hydroxybutyrate dehydrogenase, type 2 2.06 0.13
SP100 SP100 nuclear antigen 2.06 0.07
RNFT1 Ring finger protein, transmembrane 1 2.04 0.31
SFXN4 Sideroflexin 4 2.04 0.23
WDR5 WD repeat domain 5 2.03 0.39
WDR18 WD repeat domain 18 2.03 0.35
RNPC3 RNA-binding region 2.03 0.22
CD3EAP CD3e molecule, epsilon associated protein 2.03 0.47
BTN3A2 Butyrophilin, subfamily 3, member A2 2.02 0.60
TMEM216 Transmembrane protein 216 2.02 0.49
ETNK1 Ethanolamine kinase 1 2.01 0.30
RPL34 Ribosomal protein L34 2.01 0.58
ALKBH2 alkB, alkylation repair homolog 2 2.00 0.2313 (CCL13), hect domain and RLD 2 pseudogene 4 (HERC2P4), SRSF
protein kinase 1 (SRPK1), tripartite motif containing 69 (TRIM69),
G-protein signaling modulator 1 (GPSM1) and natriuretic peptide
receptor 2 (NPR2).
3.2. Determination of significantly expressed genes in CD34+ cells and
granulocytes of CML compared to control subjects
We previously mentioned that CML and control CD34+ cells shared
3553 common genes using the Venn diagram (Fig. 1 B). We compared
these common genes by Student's t-test, and defined the significantly
upregulated 41 genes in CML versus control CD34+ cells (p b 0.05)
(Table 2). The most significantly upregulated genes, in favor of CD34+
CML cells, were HINT1, TXN, SERBP1 and RPL6 (Table 2). On the other
hand, themost significantly downregulated genes in CML versus control
CD34+ cells, with more than 2.5 fold difference in gene expression,
were KCNQ1OT1, FREM2, PPP1R3F and MLLT4 (Table 3). Also, Student's
t-test determined significant genes, presented by hierarchical clustering
to describe their relation (Fig. 2). We also showed that granulocytes of
CML subjects significantly expressed 39 genes in comparison to control
subjects (Supplemental Table 2).
3.3. Signaling pathways and related gene expression affected by CML
Significantly upregulated expression of E2F1, NFKBIA, TGFBR2 and
KRAS in control subjects versus CML subjects was determined (Fig. 3A,
Table 4), while significantly upregulated genes in CML subjects were
PTPN11, CTBP2, CDK4, CDK6 and MYC in CD34+ cells (Fig. 3B, Table 4).
The genes expressed only in CML subjects, in comparison to control
(absent or sporadic), were E2F3, NFKB1 and MAPK1 (Fig. 3C, Table 4).
Regarding Imatinib inhibition related genes, the FOS and STAT1 genes
were significantly decreased (p b 0.01) in CML compared to control
subjects (Fig. 3D). PI3K/AKT and MAPK signaling pathways, affected
by BCR–ABL mutation, promoted the CD34+ cells proliferation and sur-
vival, while TGF-β signaling affected a growth of CD34+ cells (Fig. 4).
Significantly upregulated genes were PTPN11, CDK4/6 and MYC, while
KRAS, NFKBIA, and FOS were downregulated in CD34+ cells (Fig. 4,
Table 4). RUNX1 gene expression was upregulated both in CD34+ cells
and granulocytes of CML and controls (Table 4, Supplemental Table 2).
RAF1 gene expression, as part of MAPK signaling pathway, was upregu-
lated both in CD34+ cells and granulocytes of CML subjects (Table 4,
Supplemental Table 2).
4. Discussion
The results of microarray study showed that the total gene expres-
sion of CD34+ cells and granulocytes revealed 3553 and 2701 genes,
respectively in CML. The genes with the most prominent expression
in CD34+ cells were DEFA1/3, MPO, HSH2D, FBXO4, MLLT3, SRSF7,
CHST13 and ZNF180, with induction more than 3 times. The genes
overexpressed exclusively in CML granulocytes were LGALS16, HCN3,
CCL13, HERC2P4, SRPK1, TRIM69, GPSM1 and NPR2. Significantly down-
regulated genes in CML CD34+ cells, with more than 2.5 fold difference
in gene expression, were KCNQ1OT1, FREM2, PPP1R3F andMLLT4. PI3K/
AKT and MAPK signaling pathway related genes were affected by BCR–
ABLmutation, as well as TGF-β signaling. The significant difference was
observed for NFKBIA and CDK4/6 genes in PI3K/AKT activated signaling
for cell proliferation, for PTPN11, KRAS and FOS genes inMAPK signaling,
and for TGFβR1/2 and CTBP2 genes within TGF-β signaling in CD34+
cells of CML subjects.
Previous microarray studies of chronic phase CML subjects analyzed
mononuclear cells in the bone marrow [1,11,13] and peripheral blood
[14], as well as CD34+ progenitors in the bonemarrow [4,5,15] and pe-
ripheral blood [6,9,10]. Also, comparative microarray analyses were
performed in blast phase CML subjects [9–11]. We combined simulta-
neous microarray analyses of CD34+ cells and granulocytes from
Table 3
Significantly downregulated genes in CML versus control CD34+ cells, with more than 2.5 fold difference in gene expression.





KCNQ1OT1 KCNQ1 opposite strand/antisense 5.3E−05 3.71 3.63 0.42 −0.08 0.61
FREM2 FRAS1 related extracellular matrix protein 2 0.0002 3.66 3.22 0.79 −0.43 0.88
PPP1R3F Protein phosphatase 1, regul. subunit 3F 0.0003 3.60 4.35 0.67 0.75 0.67
MLLT4 Myeloid/lymphoid mixed-lineage leukemia 0.0004 3.56 3.88 0.73 0.32 0.96
ASTN2 Astrotactin 2 0.0001 3.45 4.05 0.61 0.60 0.79
BNIP3L BCL2/adenovirus E1B interact protein 3-like 0.0002 3.41 2.85 0.88 −0.56 0.72
CDRT1 CMT1A duplicated region 0.0055 3.40 2.51 1.04 −0.94 1.79
HSP90AB2P Heat shock protein 90 kDa alpha 0.0002 3.24 3.70 0.61 0.46 0.85
PGM5P2 Phosphoglucomutase 5 pseudogene 2 0.0001 3.23 3.39 0.66 0.16 0.65
ORC4 Origin recognition complex, sub 4 0.0002 3.21 3.55 0.68 0.34 0.80
MIPOL1 Mirror-image polydactyly 1 0.0004 3.17 2.90 0.98 −0.27 0.87
LRP6 Low density lipoprotein receptor-related protein 6 0.0010 3.16 1.98 0.78 −1.18 1.14
SERPINB9 Serpin peptidase inhibitor, clade B 0.0004 3.07 2.86 0.76 −0.21 0.47
CFLAR CASP8 and FADD-like apoptosis regulator 0.0021 2.95 2.19 0.92 −0.86 0.94
MALAT1 Metastasis associated lung adenocarcinoma 0.0061 2.79 1.85 2.01 −0.86 1.80
PRR20A Proline rich 20A 0.0019 2.75 2.81 0.84 0.07 0.55
CDKN2B Cyclin-dependent kinase inhibitor 2B 0.0022 2.72 1.04 0.63 −1.66 0.96
UGT2B15 UDP glucuronosyltransferase 2 family B15 0.0003 2.71 1.88 0.64 −0.83 0.54
CCDC144B Coiled-coil domain containing 144B 0.0087 2.69 3.19 0.41 0.55 0.72
RFX4 Regulatory factor X, 4 2.5E−05 2.60 1.48 0.49 −1.12 0.52
ID2 Inhibitor of DNA binding 2 0.0006 2.60 1.69 0.39 −0.78 0.66
GZMM Granzyme M (lymphocyte met-ase 1) 0.0018 2.55 0.25 0.43 −2.31 0.44
ZNF215 Zinc finger protein 215 0.0001 2.55 1.33 0.47 −1.22 0.65
SLC19A3 Solute carrier family 19, member 3 0.0003 2.51 2.26 0.66 −0.25 0.52
Table 2
Significantly upregulated genes in CML versus control CD34+ cells, with more than 2 fold difference in gene expression.





HINT1 Histidine triad nucleotide binding protein 1 2.5E−07 2.25 0.68 0.39 2.93 0.32
TXN Thioredoxin 2.1E−06 2.06 −0.84 0.38 1.22 0.44
SERBP1 SERPINE1 mRNA binding protein 1 4.5E−06 2.10 −0.09 0.34 1.93 0.39
RPL6 Ribosomal protein L6 6.5E−06 2.15 −1.08 0.44 1.07 0.42
RPLP0 Ribosomal protein, large, P0 1.1E−05 2.49 −1.72 0.49 0.77 0.46
HSPA8 Heat shock 70 kDa protein 8 1.1E−05 2.14 −1.26 0.45 0.88 0.32
RPS18 Ribosomal protein S18 1.2E−05 2.60 −0.05 0.46 2.54 0.49
GCSH Glycine cleavage system protein H 1.4E−05 2.38 −1.19 0.25 1.19 0.30
H2AFZ H2A histone family, member Z 1.7E−05 2.03 −1.47 0.42 0.56 0.40
H2AFV H2A histone family, member V 1.8E−05 2.21 0.56 0.54 2.77 0.58
C1QBP Complement component 1, q subcomp. binding protein 1.8E−05 2.54 −1.56 0.40 0.98 0.53
RPS12 Ribosomal protein S12 2.0E−05 2.13 −1.09 0.36 1.04 0.48
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 3.4E−05 2.21 0.94 0.58 3.16 0.34
RPLP1 Ribosomal protein, large, P1 5.5E−05 2.20 −1.12 0.44 1.08 0.48
HIST1H4C Histone cluster 1, H4 6.2E−05 2.47 0.06 0.49 2.78 0.69
PPA1 Pyrophosphatase (inorganic) 1 6.5E−05 2.16 −0.66 0.46 1.50 0.53
NDUFA8 NADH dehydrogenase 1α subcomplex, 8, 19 kDa 6.5E−05 2.41 0.01 0.17 2.27 0.39
METTL5 Methyltransferase like 5 7.1E−05 2.05 −0.50 0.18 1.36 0.32
TFDP1 Transcription factor Dp-1 7.3E−05 2.19 −0.31 0.24 1.94 0.49
EEF1B2 Eukaryotic translation elongation factor 1β2 7.6E−05 2.27 0.12 0.65 2.39 0.35
HMGN2 High mobility group nucleosomal bind domain 2 8.8E−05 2.41 −1.06 0.29 1.35 0.58
RPL6 Ribosomal protein L6 0.0002 2.00 0.39 0.69 2.39 0.56
RPL7 Ribosomal protein L7 0.0003 2.00 0.13 0.60 2.13 0.55
DEK DEK oncogene 0.0003 2.06 −0.30 0.60 1.76 0.51
SNRPE Small nuclear ribonucleoprotein polypept E 0.0003 2.10 −0.99 0.54 1.11 0.25
RPL26 Ribosomal protein L26 0.0004 2.04 −1.09 0.69 0.95 0.30
NUCB2 Nucleobindin 2 0.0004 2.27 −0.38 0.10 1.63 0.42
RPSAP58 Ribosomal protein SA pseudogene 58 0.0005 2.06 −1.23 0.63 0.83 0.20
TMEM14B Transmembrane protein 14B 0.0006 2.14 −0.89 0.68 1.25 0.41
MRPL1 Mitochondrial ribosomal protein L1 0.0006 2.25 0.97 0.12 2.90 0.41
RPS3A Ribosomal protein S3A 0.0009 2.11 −0.78 0.96 1.33 0.28
TTC27 Tetratricopeptide repeat domain 27 0.0016 2.19 0.97 0.28 3.08 0.52
CCT2 Chaperonin containing TCP1, subunit 2 0.0017 2.13 0.23 0.62 2.17 0.46
FABP5 Fatty acid binding protein 5 0.0017 2.14 −0.37 0.22 1.69 0.53
RPS2 Ribosomal protein S2 0.0026 2.40 −0.32 1.25 2.08 0.43
RPS3A Ribosomal protein S3A 0.0030 2.08 −0.07 0.94 2.01 0.50
SOCS2 Suppressor of cytokine signaling 2 0.0030 2.07 1.10 0.34 2.96 0.58
MCM5 Minichromosome maintenance complex comp 5 0.0032 2.04 0.37 0.11 2.55 0.29
RPS3A Ribosomal protein S3A 0.0047 2.79 0.68 1.67 3.47 0.70
BRP44 Brain protein 44 0.0060 2.12 0.71 0.14 2.52 0.59
RPL7 Ribosomal protein L7 0.0065 2.04 0.25 1.16 2.29 0.40
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Fig. 3. BCR–ABL activated gene expression profile in CD34+ cells of CML. (A) Upregulated genes in controls. (B) Upregulated genes in CML. (C) Genes expressed only in CML. (D) Inhibition
of cellular proliferation after Imatinib therapy.
379V.P. Čokić et al. / Blood Cells, Molecules and Diseases 55 (2015) 373–381peripheral blood of chronic phase CML subjects. Comparing the controls
and CML CD34+ cells we found that 64 genes were overexpressed ex-
clusively in CML CD34+ cells more than 2 fold. Their products are in-
volved in the regulation of different cellular functions including cell
cycle (WDR5, WDR18), apoptosis (CASP3, CASP6), tumor suppression
(ARMCX1), and regulation of transcription (ZNF180). Expanded micro-
array analysis of granulocytes revealed a significant difference in ex-
pression pattern of 39 genes between CML and healthy donors. In
contrast to presented DEFA1 and DEFA3 upregulated gene expression
in CD34+ cells of chronic phase CML subjects, genes responsible for
anti-pathogen response (DEFA1, DEFA3, DEFA4) were downregulated
in blast phase CML cells [13].
The largest difference between chronic phase CML subjects and nor-
mal donors was obvious in CD34+ cells, including the downregulation
of genes encoding inhibitors of cell proliferation in chronic phase CML
[15]. Among genes linked to the inhibition of cellular proliferation by
Gleevec: STAT1 and FOS had significantly decreased expression in CML,
whereas MAP2K1 and RAF1 had very similar level of expression in
CML and controls. The following genes CDK4, CDK6, MYC, CTBP2, and
PTPN11 had increased expression and NFKBIA, E2F1, KRAS and TGFBR2
genes had reduced expression in CML-associated genes of CD34+
cells. Extracellular-regulated kinase (ERK) was significantly upregu-
lated in primary BCR–ABL-positive cells (MAPK1). Regarding genes
involved in the PI3K pathway, its substrate AKT and the downstreamFig. 2.Hierarchical clustering of genes expressed in CML and control CD34+ cells. Hierarchical c
control CD34+ cells, determined by Student's t-test. The color indicates the relative fold express
changed expression, while gray stands for absent expression per each examined sample. The
representing similarities among examined cells. The genes and arrays correlations are uncentemolecules NFκB and Bcl-xl were significantly upregulated in CML
CD34+ cells [4]. According to our data, AKT and Bcl-xl had decreased
expression while NFKB1 had increased expression in CML CD34+
cells, but no significant difference was observed. Moreover, the up-
regulation has been reported in CD34+ compartment of proteins
within the STAT pathway and MYC, and downregulation of MDM2,
MEK, AKT and NFκB proteins [16]. It has been reported that the
BCR–ABL adapter protein CRKL has also been upregulated in CML
CD34+ cells, but not in our results at mRNA level. Within the TGF-β
signaling pathway, other report has shown that TGF-β1 itself as
well as SMAD2 and SMAD4 were significantly upregulated in CML
CD34+ cells, in contrast to our results [4].
The bonemarrowCD34+ cells expressed 9 cell cycle driving genes at
particularly higher levels than circulating CD34+ cells [17]. According to
those results cycling activity of bone marrow CD34+ cells was higher
than in peripheral blood CD34+ cells. We found a significant downreg-
ulation of FOS in CML CD34+ cells. FOS had a role in growth suppression
and apoptosis of many cell types. Therefore, the downregulation of FOS
might be liable for increased proliferation of CML CD34+ cells [5]. In ac-
cordance to our results, the upregulation of CDK4 gene expression has
been reported in CML, as a gene involved in cell cycle [13]. The upregu-
lation of the E2F1 transcription factor lead to a molecular mechanism
that initiated the proliferation of hematopoietic stem and progenitor
cells [17]. The cell cycle-initiating transcription factor E2F1, thatlustering of statistically significant different (p b 0.05) gene expression, between CML and
ion of each gene: red indicates increased expression, green negative expression, black no
total gene expression of CML and control CD34+ cells is also clustered (upper image)
red. The gene description is provided in Table 3t
,
Table 4
BCR–ABL activated signaling pathway related genes in CD34+ cells of CML and healthy control origin.







AKT2 v-akt murine thymoma viral oncogene homolog 2 0.87 0.18 0.55 0.68
CBL Cbl proto-oncogene, E3 ubiquitin protein ligase 0.52 0.43 0.34 0.42
CDK4 Cyclin-dependent kinase 4 0.02 −1.58 −1.06 0.29 0.08 0.50
CDK6 Cyclin-dependent kinase 6 0.003 −1.42 0.42 0.63 1.88 0.47
CDKN1A Cyclin-dependent kinase inhibitor 1A 2.66 0.69
CDKN1B Cyclin-dependent kinase inhibitor 1B 0.87 0.9 1.23 0.31
CRK v-crk sarcoma virus CT10 oncogene homolog 1.5 0 −0.08 0.42
CTBP1 C-terminal binding protein 1 −0.42 0 0.23 1.09
CTBP2 C-terminal binding protein 2 0.007 −1.08 0.03 0.31 1.01 0.27
E2F1 E2F transcription factor 1 0.03 2.00 0.19 0.69 −2.18 0.44
E2F3 E2F transcription factor 3 0.65 0 1.06 0.74
FOS FBJ murine osteosarcoma viral oncogene homolog 0.007 1.79 2.46 0.87 0.42 1.16
GRB2 Growth factor receptor-bound protein 2 1.8 0.19
HDAC1 Histone deacetylase 1 0.26 0.21
HDAC2 Histone deacetylase 2 −0.5 0.14
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 0.003 1.06 1.4 0.51 0.34 0.31
MAP2K1 Mitogen-activated protein kinase kinase 1 0.8 0 0.46 0.57
MAPK1 Mitogen-activated protein kinase 1 0.64 0.18
MYC v-myc myelocytomatosis viral oncogene homolog 0.018 −2.93 −2.0 0.27 0.29 0.85
NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 0.57 0 0.97 0.30
NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, α 0.02 1.95 4.31 0.72 2.36 1.21
PIK3CB Phosphoinositide-3-kinase, catalytic, β polypeptide 1.18 0.13
PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 1 0.72 0 1.34 0.02
PTPN11 Protein tyrosine phosphatase, non-receptor type 11 0.04 −1.14 0.45 0.46 1.46 0.43
RAF1 v-raf-1 murine leukemia viral oncogene homolog 1 2.06 0 1.66 0.32
RUNX1 runt-related transcription factor 1 4.47 1.1 4.15 0.56
STAT1 Signal transducer and activator of transcription 1 0.003 1.30 3.6 0.55 2.22 0.36
STAT5A Signal transducer and activator of transcription 5A 1.32 0.24 1.10 0.57
TGFBR1 Transforming growth factor, β receptor 1 0.6 0.23
TGFBR2 Transforming growth factor, β receptor II 0.023 0.48 1.67 0.18 1.20 0.14
380 V.P. Čokić et al. / Blood Cells, Molecules and Diseases 55 (2015) 373–381promoted cell cycle progression, showed higher expression in bone
marrow CD34+ cells than in peripheral blood CD34+ cells [18]. In
our study, E2F1 gene expression was downregulated in CML
CD34+ cells compared to control CD34+ cells.
Results of this study highlighted the difference in gene expression be-
tween primitive and mature cells of CML and control subjects, with theFig. 4. BCR–ABL activated signaling pathways in CD34+ cells of CML origin. (+p) phosphorylati
empty boxes represent downregulated genes, while in gray boxes represent upregulated genes
represent unexpressed or sporadically expressed genes. Red bolded gene symbols represent siaccent on theCD34+cells that direct thepathogenic course ofmalignancy.
The presence of BCR–ABL fusion gene significantly modified the observed
genes in PI3K/AKT, MAPK and TGF-β signaling pathways, enhancing its
influence on CD34+ cell proliferation, apoptosis and cell growth.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bcmd.2015.08.002.on;→ stimulation,┴ inhibition; dotted lines define gene function; bolded gene symbols in
in CML vs. controls (corresponding to Table 4). Non-bolded gene symbols in empty boxes
gnificantly different genes in CML vs. controls.
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